Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRD1 | P41143 | 10/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 5/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | PRCP | P42785 | 2/20 | 0.33 |
| ▸ | CTSC | P53634 | 2/20 | 0.32 |
| ▸ | CSK | P41240 | 1/20 | 0.31 |
| ▸ | PSMB1 | P20618 | 1/20 | 0.31 |
| ▸ | PSMB9 | P28065 | 1/20 | 0.31 |
| ▸ | PSMB5 | P28074 | 1/20 | 0.31 |
| ▸ | PSMB10 | P40306 | 1/20 | 0.31 |
| ▸ | PSMB2 | P49721 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22503730 | 0.89 | MME (0.40) | — | |
| SCHEMBL30799829 | 0.89 | GHSR (0.37) | OPRD1OPRM1OPRK1CTSC | |
| SCHEMBL5077777 | 0.89 | MME (0.40) | — | |
| SCHEMBL5077779 | 0.89 | MME (0.40) | — | |
| SCHEMBL3268628 | 0.88 | OPRD1 (0.33) | OPRD1OPRM1OPRK1 | |
| Hydrochloric Acid SCHEMBL21724486 | 0.88 | MME (0.39) | — | |
| Hydrochloric Acid SCHEMBL21724484 | 0.88 | MME (0.39) | — | |
| SCHEMBL24270549 | 0.87 | SMN1; SMN2 (0.33) | OPRD1OPRM1PRCPCTSCCSK | |
| SCHEMBL14065661 | 0.87 | SMN1; SMN2 (0.33) | OPRD1OPRM1PRCPCTSCCSK | |
| SCHEMBL13079794 | 0.87 | MEN1 (0.36) | OPRK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | Cadila Corporate Campus (IN) | 2013-05-30 | — | — | US | disclosed |
| WO-2012017391-A2 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | CADILA PHARMACEUTICALS LIMITED (IN) | 2012-02-09 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130137852-A1 | NOVEL COMPOUNDS AS DPP-IV INHIBITORS AND PROCESS FOR PREPARATION THEREOF | DPP4, DPP7, DPP3 | OPRD1 4051/4885OPRM1 4551/4885OPRK1 3818/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.